CN1065129C - Medicine good for heart - Google Patents
Medicine good for heart Download PDFInfo
- Publication number
- CN1065129C CN1065129C CN94102799A CN94102799A CN1065129C CN 1065129 C CN1065129 C CN 1065129C CN 94102799 A CN94102799 A CN 94102799A CN 94102799 A CN94102799 A CN 94102799A CN 1065129 C CN1065129 C CN 1065129C
- Authority
- CN
- China
- Prior art keywords
- peak
- minutes
- cmgsp
- biological activity
- cardiac muscle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to a medicine (medicine good for the heart) for treating cardiomyopathies. Cardiac muscle cell growth stimulating peptide (CMGSP) is extracted from the hearts of healthy young mammals such as anthony pigs, cattle, etc., and the molecular weight of the CMGSP is from 5000 to 12000Da. In fact, the present invention is a polypeptide mixture which has stable bioactivity, and can stimulate the synthesis of primary culture cardiac muscle cell DNA and protein, promote the cleavage and the proliferation of the cardiac muscle cells, and protect the cardiac muscle cell membranes. When the medicine is used in clinics, oral administration and intramuscular injection can be adopted, and the medicine can be matched with other medicines to dripped into the vein; the present invention has good effect on treating cardiomyopathies.
Description
That the present invention relates to is a kind of CMGSP (CMGSP), clinical practice resuming treatment after myocarditis and cardiac operation.
Having the myocardial cell DNA of stimulation and proteic synthetic in the prior art, promote the stimulating factor of cell division propagation, mainly is to extract from the cardiac muscle of spontaneous hypertensive rat or experimental hypertension animal, and biological activity is lower.
The object of the present invention is to provide a kind of from the cardiac muscle of healthy childhood of mammal, extract have a higher bioactive CMGSP (CMGSP), for being used for the treatment of resuming treatment after cardiomyopathy and the cardiac operation clinically.Can oral and intramuscular injection, or with other medicines compatibility vein.
Medicine good for heart medicine of the present invention is a kind of stable CMGSP (CMGSP), has following feature:
(1) stable in the PH2--9 scope;
(2) heating 95--100 ℃ 10 minutes, biological activity does not change under 60--70 ℃ of 30 minutes condition;
(3) at the multiple protein hydrolytic enzyme, 37 ℃, loss of bioactivity under 2 hours conditions;
(4) under aqueous solution 22--30 ℃ condition, can form polymer, but the biological activity change is not obvious;
(5) adding under the 3--8% mannitol lyophilizing air-proof condition, room temperature storage 1.5 years was stored 2 years for 4 ℃, stored 3 years for-20 ℃, and biological activity does not change;
(6) under the HPLC analysis condition, to form by 4 components, the each component relative peak area is: peak 1 10.4%, peak 2 6.4%, peak 3 36.3%, peak 4 7.3%, each peak retention time was respectively the peak 1 2.88 minutes, peak 2 3.93 minutes, peak 3 5.09 minutes, peak 4 7.41 minutes.Each component is tested separately, and biological activity is all arranged;
(7) analyze through SDS--PAGE, show 2 bands, its molecular weight is respectively 8500Da, and 10800Da analyzes through HPLC, and the number-average molecular weight of CMGSP is 9800Da, and weight average molecular weight is l0500Da, and 2 components all have biological activity.
Be two distinctive absworption peaks to be arranged through ultraviolet scanning spectrum figure at l95 ± 2nm and 255 ± 2nm place.
Medicine good for heart is the synthetic and protein synthesis of DNA that has stimulation cardiac muscle cells of former generation for a class, promotes that the division growth of myocardial cell and the molecular weight of protecting myocardial cell film are the micromolecule polypeptide mixture of 5000--l2000Da.
It is divided into four components, and single component or two kinds and many components are used in combination all effective.
Accompanying drawing 1 is analyzed for HPLC of the present invention
Medicine biological activity technique of expression example of the present invention:
Get SD mouse embryo (pregnant l2--l6 days), aseptic isolating cardiac, the trypsin separating myocardium cell is after DMEM culture medium washing 3 times, with DME/Fl2 culture medium preparation 2-5 * 10 that contain the l0% calf serum
5Individual cell/ml puts in 96 well culture plates, every hole 0.15ml, 37 ℃, 5%CO
2Hatched under the condition 24 hours.After changing liquid with serum-free DME/F12 culture medium, experimental port adds the CMGSP in 5-40 μ g/ hole, control wells only adds the DME/F12 culture medium, continue to cultivate 48 hours, every hole adds 5 μ lMTT (1.5mg/ml, the preparation of DME culture medium), continues to cultivate 4--6 hour, every hole adds dimethyl sulfoxide 100 μ l cessation reactions puts and surveys the OD value under the microplate reader 570nm condition, with experimental port/control wells＞1.7 times for activity is arranged.Measurement result is as follows:
CMGSP is to the influence of Culture Center myocyte mitochondrial dehydrogenase vigor
| n | 0D | Multiple | The P value | |
| Matched group experimental group 5 10 20 40 | 8 (μg) 4 4 4 4 | 0.108±0.01 0.143±0.02 0.233±0.03 0.243±0.02 0.195±0.04 | 1.3 2.2 2.3 1.8 | ＞0.05 ＜0.01 ＜0.01 ＜0.05 |
The pharmacological action of medicine of the present invention is achieved as follows:
Get the SD rat, male and female are not limit, every kg body weight injection isoproterenol 2mg, and after 24 hours, with the CMGSP treatment, every rat is given CMGSP 4mg, once a day, continuous three days. compares with physiological saline; 3,TYPE：AREA PERCENT RUN NUMBER：1 INDEX：1 WAVELENGTH：254nmPEAK# AREA％ RT AREA BC 1 0．061 0．28 128537 02 2 0．121 0．98 257530 02 3 1．015 2．69 2150812 02 4 ① 10．356 2．88 21943700 02 5 1．844 3．14 3908476 02 6 1．041 3．35 2205808 02 7 0．874 3．67 1851837 02 8 ② 6．431 3．93 13629270 08 9 1．533 4．51 3248245 06 10 ③ 36．337 5．09 76999441 08 11 0．123 5．69 261684 06 12 0．182 6．16 385149 06 13 0．204 6．36 432545 06 14 0．329 6．75 696258 06 15 ④ 7．266 7．41 15398112 06 16 2．333 8．29 4942818 06 17 0．667 8．75 1414685 06 18 1．387 9．09 2938040 06 19 0．24 10．19 508311 06 20 1．352 11．15 2864678 06 21 0．804 11．22 1705749 06 22 5．537 12．01 11731315 06 23 3．617 12．13 3426588 06 24 0．348 12．27 737765 0628 0.632 17.01 1,340,201 06 29 0.089 17.11 188,882 06 30 17.14 146,296 06 31 0.799 17.37 1,692,180 06 32 0.311 19.66 659510 07TOTAL, 100 211906886 pathological sections O.069, the pathological changes difference of observing treatment group and matched group.
Found that:
The pathological change of matched group mainly shows as myocardial cell degeneration (the blister sample becomes the master), and serious necrosis sees that cardiac muscle cross striation shoals around the little A more, and phenomenon of rupture is arranged between the myocardial cell, and the lymphocytic infiltration degree is obvious.And the degree of CMGSP group myocardial cell degeneration necrosis is light than matched group all, and the quantity of non-viable non-apoptotic cell is also less, and the lymphocytic infiltration degree is light, the myocardial cell clear in structure.
Medicine of the present invention can use separately, also can promote myocardial metabolism, repair myocardial damage with other, improves myocardial blood circulation Chinese medicine and western medicine folk prescription or compound recipe and share.
Claims (3)
1. myocarditis curative, CMGSP (GMGSP) is that preparation is extracted from healthy childhood mammal cardiac muscle, it is characterized in that:
(1) stable in the pH2-9 scope;
(2) heating 95-100 ℃ 10 minutes, biological activity does not change under 60-70 ℃ of 30 minutes condition;
(3) at the multiple protein hydrolytic enzyme, loss of bioactivity under 37 ℃ of 2 hours conditions;
(4) under aqueous solution 22-30 ℃ condition, can form polymer but biological activity changes not obvious;
(5) adding under the 3-8% mannitol lyophilizing air-proof condition, room temperature storage 1.5 years was stored 2 years for 4 ℃, stored 3 years for-20 ℃, and biological activity does not change;
(6) under the HPLC analysis condition, to form by 4 components, the each component relative peak area is: peak 1 10.4%, peak 2 6.4%, peak 3 36.3%, peak 4 7.3%, each peak retention time was respectively the peak 1 2.88 minutes, peak 2 3.93 minutes, peak 3 5.09 minutes, peak 4 7.41 minutes.Each component is tested separately, and biological activity is all arranged;
(7) analyze through SDS-PAGE, show 2 bands, its molecular weight is respectively 8500Da, and 10800Da analyzes through HPLC, and the number-average molecular weight of GMGSP is 9800Da, and weight average molecular weight is 10500Da, and 2 components all have biological activity.
2. myocarditis curative according to claim 1, wherein CMGSP ultraviolet scanning spectrum figure is, at 195 ± 2nm and 255 ± 2nm place 2 distinctive absworption peaks is arranged.
3. according to the described myocarditis curative of claim 1; wherein CMGSP is the synthetic and protein synthesis of DNA that can stimulate formerization cardiac muscle cells, promotes that the division growth of myocardial cell and the molecular weight of protecting myocardial cell film are the micromolecule polypeptide mixture of 5000-12000Da.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN94102799A CN1065129C (en) | 1994-03-15 | 1994-03-15 | Medicine good for heart |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN94102799A CN1065129C (en) | 1994-03-15 | 1994-03-15 | Medicine good for heart |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1108540A CN1108540A (en) | 1995-09-20 |
| CN1065129C true CN1065129C (en) | 2001-05-02 |
Family
ID=5030790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN94102799A Expired - Lifetime CN1065129C (en) | 1994-03-15 | 1994-03-15 | Medicine good for heart |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1065129C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010006476A1 (en) * | 2008-07-15 | 2010-01-21 | 大连珍奥药业有限公司 | Myocardial peptide, preparation method and uses thereof |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1300171C (en) * | 2003-06-04 | 2007-02-14 | 大连珍奥药业有限公司 | Preparation of myocardium peptide |
| CN101265292B (en) * | 2007-03-16 | 2011-09-14 | 大连珍奥药业有限公司 | Polypeptides substances, preparing method and use thereof |
| CN102382127A (en) * | 2011-09-23 | 2012-03-21 | 复旦大学 | Myocardial small molecular compound for idiosyncratically promoting proliferation of myocardial cells and application thereof |
| CN110302359A (en) * | 2018-08-13 | 2019-10-08 | 广东思峰生物科技有限责任公司 | A kind of preparation reducing blood glucose, preparation method and applications |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1033564A (en) * | 1987-12-24 | 1989-07-05 | 北京市护国寺中医医院 | Sick compound ointment of the treatment obstruction of heart-QI and method for making thereof |
| CN1061156A (en) * | 1990-11-08 | 1992-05-20 | 刘学博 | A kind of manufacturing technique method of Xinnaomaitong injecta for promoting blood circulation |
| CN1081323A (en) * | 1993-06-30 | 1994-02-02 | 翁是强 | The prescription of solid beverage for health-care and processing technology |
-
1994
- 1994-03-15 CN CN94102799A patent/CN1065129C/en not_active Expired - Lifetime
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1033564A (en) * | 1987-12-24 | 1989-07-05 | 北京市护国寺中医医院 | Sick compound ointment of the treatment obstruction of heart-QI and method for making thereof |
| CN1061156A (en) * | 1990-11-08 | 1992-05-20 | 刘学博 | A kind of manufacturing technique method of Xinnaomaitong injecta for promoting blood circulation |
| CN1081323A (en) * | 1993-06-30 | 1994-02-02 | 翁是强 | The prescription of solid beverage for health-care and processing technology |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010006476A1 (en) * | 2008-07-15 | 2010-01-21 | 大连珍奥药业有限公司 | Myocardial peptide, preparation method and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1108540A (en) | 1995-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WHITE et al. | Viscosity of β-D-glucan as a factor in the enzymatic improvement of barley for chicks | |
| Maciag et al. | High and low molecular weight forms of endothelial cell growth factor. | |
| Bischoff | A satellite cell mitogen from crushed adult muscle | |
| EP0105014A2 (en) | Repair of tissue in animals | |
| Zick et al. | Insulin stimulates phosphorylation of serine residues in soluble insulin receptors | |
| CN1065129C (en) | Medicine good for heart | |
| Smellie et al. | The nucleic acid metabolism of animal cells in vitro: I. The incorporation of 14C-formate | |
| Schneider et al. | Effects of alloxan diabetes on duodenal calcium-binding protein in the rat | |
| CN101020715A (en) | Process of extracting and preparing deer nerve growth factor (DEER NGF) | |
| Aldinio et al. | Monosialoganglioside internal ester stimulates the dopaminergic reinnervation of the striatum after unilateral hemitransection in rat | |
| DK445686A (en) | TUMOR CELL GROWTH INHIBITANT PLANET EXTRACT - PREPARATIONS AND PREPARATION OF A SIMILAR ACTIVE SUBSTANCE MIXTURE AND OF A PROTEINER, PEPTIDEROG / OR PROTEINOUS SUBSTANCES Enriched Fractionation of a Pollen | |
| US20150148309A1 (en) | Saccharide fraction from wheat, isolation process and field of use of the invention | |
| EP3834834A1 (en) | Drug used for treating tissue necrosis or for improving cardiac function | |
| Coughlin et al. | Antiserum to a new neuronal growth factor: effects on neurite outgrowth | |
| Hulyalkar et al. | Arylsulfatase A variants in patients with alcoholism | |
| RU2214259C2 (en) | Lectin from robinia pseudoacacia and its application | |
| Humpel et al. | Monitoring release of neurotrophic activity in the brains of awake rats | |
| Bashey et al. | Increased biosynthesis of glycosaminoglycans by scleroderma fibroblasts in culture | |
| Hsueh et al. | A growth factor for animal cells derived from peptone: I. Isolation and characterization of the growth factor | |
| US6660305B1 (en) | Composition for stimulating the synthesis of the melanic pigment and process for obtaining it | |
| CN113880961A (en) | Gluconhexaose, preparation method thereof, application thereof and hair regeneration preparation | |
| CN113143970A (en) | Methods and compositions for promoting tissue repair in diabetic subjects | |
| CN111110827A (en) | External-application pharmaceutical composition, preparation method and application thereof | |
| EP0759069B1 (en) | Beta taipoxin as a cell growth factor and method | |
| Chaminade et al. | Noncollagenous proteins in cartilage of normal subjects and patients with degenerative joint disease. A gel electrophoretic study |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: ZHENAO PHARMACEUTICAL CO., LTD., DALIAN CITY Free format text: FORMER OWNER: NO.458 HOSPITAL, PLA Effective date: 20020521 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20020521 Address after: 116620, Liaoning, Dalian double D port, life all the way No. 88 Patentee after: Dalian Zhen-Ao Pharmaceutical Co., Ltd. Address before: 510602 No. 801 Dongfeng East Road, Guangdong, Guangzhou Patentee before: Hospital No.458, Chinese P.L.A. |
|
| C17 | Cessation of patent right | ||
| CX01 | Expiry of patent term |
Expiration termination date: 20140315 Granted publication date: 20010502 |